This major endocrine action of FGF21 results in a combination of effects including control of lipolysis, clearance of excessive FFAs, enhancing expenditure of the stored lipid energy by mitochondrial substrate oxidation, catabolism and uncoupling, and therefore, negatively regulating hepatic or tissue steatosis, and adiposity 13-15. The gene discussed is FGF21; the disease is steatosis.